Pet nutrition and tech companies raised new funding across four rounds

Four companies with connections to pet nutrition and healthcare closed funding rounds in recent weeks, directing capital toward production facilities, protein ingredient development, distribution infrastructure, and breeding programs.

The rounds and their deployment plans

Mumbai-based pet food company Lickicious raised $1.9 million through a combination of equity and institutional debt. Early-stage venture capital firm Prath Ventures led the institutional portion, and ISV Capital participated. The company will direct a substantial share of the proceeds toward building a 60,000-square-foot manufacturing and distribution facility. Additional capital will fund capacity expansion, product development, hiring, operating systems, national distribution expansion, and exploration of new categories, formats, and sales channels. Lickicious, which launched in 2023 as the digital-first brand of Indian pet food and nutrition company Nuvexo Wellness, stated that $10 million in annual revenue is its next target and that it aims to become one of India's top three pet food companies within the next decade.

Belgian biotechnology company MAASH raised a $14.1 million package structured as $6.8 million in equity from five new investors, Ambra Capital, InvestPro, Bpifrance, Nordzucker, and Tereos, plus $5 million from public investment bank Bpifrance and a $2.3 million loan. MAASH will use the capital to scale production of LoCylia, a mycoprotein ingredient derived through fermentation and formulated for blended meat and pet food applications. In pet food formulations, LoCylia serves as a substitute for fishmeal, soy, and legumes, which supply amino acids. The funding will also finance the launch of a demonstration facility in Carling-Saint-Avold, France, and ready the company for production at industrial scale. MAASH operates as a B2B ingredient supplier specializing in fermentation and mycoprotein production, with facilities in Belgium and France.

Indian healthcare supply chain startup DocPharma closed a $2 million pre-Series A round led by investment advisory firm Equentis, with participation from existing investors 100Unicorns, Vinners, and a group of strategic angel investors. The company will deploy the capital to grow its healthcare fulfillment network from 12 cities to more than 50 cities and to open 100 new licensed dark stores, which are retail-style warehouses and distribution centers, nationwide. DocPharma partners with more than 30 healthcare and wellness platforms, a group that includes e-pharmacies, hospitals, health insurers, corporate wellness companies, and direct-to-consumer brands. Some of those direct-to-consumer brands operate in pet care. The company's network carries more than 40,000 SKUs and supports partner platforms in delivering medicines and healthcare products in 30 minutes or less. The startup has completed more than 800,000 orders to date.

Edinburgh-based black soldier fly genetics company Beta Bugs secured $1.1 million to speed commercialization of its HiPer-Fly genetics, grow its international customer base, and expand its network of strategic partners. Angel investment syndicate TRICAPITAL Angels led the round, and economic development agency Scottish Enterprise provided support. The capital will also help Beta Bugs respond to demand from commercial insect farming operations for black soldier fly genetics that deliver better performance and greater consistency. Beta Bugs developed HiPer-Fly through selective breeding aimed at improving growth, yield, survival, and production consistency. Following successful trials in early 2026, the company partnered with Israeli agritech firm FreezeM to distribute the genetics via PauseM, a patent-pending biotechnology product that halts the life cycle of newly hatched black soldier fly larvae for as long as 21 days. Derek Shaw, Commercial Director at Scottish Enterprise, said the investment will let Beta Bugs continue developing its breeding program, strengthen commercial relationships internationally, and expand availability of HiPer-Fly genetics to black soldier fly producers worldwide.

The infrastructure pattern across the four rounds

Three of the four rounds fund physical infrastructure rather than customer acquisition or brand marketing. Lickicious is constructing a 60,000-square-foot facility. MAASH is financing a demonstration plant in France to validate production at industrial scale. DocPharma is opening 100 dark stores to compress delivery times from hours to minutes.

The fourth round, Beta Bugs' $1.1 million, funds genetics development and commercial partnerships rather than farming capacity, but it still addresses production. Black soldier fly larvae function as a protein ingredient in pet food formulations, and Beta Bugs sells genetics to insect farmers who supply protein to pet food manufacturers. The capital finances breeding programs and commercial relationships, not consumer-facing operations.

If your category depends on alternative protein or you're watching the India market, subscribe to PetRetailNews.

The retail gaps in the announcements

None of the four companies disclosed a retail partner, a shelf placement, or a distribution agreement in their funding announcements. Lickicious said it will explore new sales channels and expand its national reach, but did not specify whether that means independent pet retail, regional chains, or e-commerce platforms. MAASH operates as a B2B ingredient supplier, not a finished-goods brand, so its route to retail shelves runs through the pet food manufacturers it supplies. DocPharma partners with direct-to-consumer pet care brands, but the company did not identify them or indicate whether any are pursuing brick-and-mortar retail. Beta Bugs sells to insect farmers, who sell to ingredient processors, who sell to pet food manufacturers, placing it three steps from a store shelf.

The capital these companies raised finances the infrastructure that would allow them to scale if retail demand appears, but the announcements do not confirm that demand exists today. A 60,000-square-foot facility and a demonstration plant respond to anticipated orders, not current ones.

Our read on the production-first allocation

The infrastructure emphasis suggests that investors believe the bottleneck in alternative protein, India pet food, and healthcare logistics is production capacity, not consumer willingness to purchase. If the constraint sits on the supply side, then the brands and ingredient suppliers that build capacity now secure the contracts when a retailer or a manufacturer wants to scale a launch.

Production capacity without confirmed retail demand becomes overhead. A facility running below capacity because retail partnerships failed to materialize costs more than no facility at all. MAASH's demonstration plant in France validates that industrial-scale production is feasible, but it does not validate that a pet food manufacturer will reformulate around mycoprotein at the volume the plant needs to break even.

For a buyer or a store owner, watch whether any of these funded companies announce a retail partnership or a co-manufacturing agreement in the next six months. If they do, the infrastructure they are building now becomes relevant to your shelf. If they do not, the funding rounds were placed on a future that has not materialized yet.

← Back to the Newsdesk